If you have CLL or SLL and have been treated with venetoclax we need your help.
Lymphoma Canada is preparing a submission for the panCanadian Oncology Drug Review (pCODR) for:
—Venetoclax for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have received at least one prior therapy; this includes patients with 17p deletion
You can help by completing our survey, which will provide us with the patient input required for the submission. pCODR uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs.
BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.
You do not need to live in Canada to complete this survey.
The survey will be open until midnight Pacific Time on Friday, July 8th and should only take 10 minutes of your time.
Please share this link and help us spread the word.
Thank you for your support.
Lymphoma Canada
